Vivimed Labs Equity Trading Resumes Dec 18 After Suspension Revocation
Trading in Vivimed Labs Limited equity shares will resume on December 18, 2025, following the revocation of suspension by BSE and NSE. The company has complied with regulatory norms, including SEBI (LODR) Regulations, 2015.
The resumption of trading after a suspension is a significant event that directly impacts the company's stock liquidity, investor confidence, and market accessibility.
The revocation of trading suspension is a positive development for the company and its shareholders, enabling liquidity and price discovery.
Vivimed Labs Limited has announced the revocation of the suspension on the trading of its equity shares by both BSE Limited and the National Stock Exchange of India Limited (NSE).
The circulars from BSE and NSE, dated December 10, 2025, indicate that trading in Vivimed Labs' equity shares will resume effective December 18, 2025. The shares will be traded under the 'T' group and will be part of the Special Pre-open Session for Relisted Scrips.
This development signifies a crucial step forward for the company, aiming to restore liquidity and facilitate price discovery for its shareholders. Vivimed Labs stated that it has diligently fulfilled all regulatory requirements, particularly addressing prior non-compliances under SEBI (LODR) Regulations, 2015. The company expressed gratitude to the exchanges and its shareholders for their support during the suspension period and looks forward to resuming trading with a commitment to transparency and growth.
What to do with a filing like this
Vivimed Labs Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vivimed Labs Limited. Read the original for the full detail.